Vivek Ramaswamy, the founder of Roivant Sciences (Nasdaq: ROIV), has taken a bold step and resigned from his board position to focus on his ambitious U.S. presidential campaign. This news has left the business world abuzz, as Roivant Sciences has made a name for itself as a game-changer in the biopharmaceutical industry.
In 2014, Vivek set out to revolutionize drug development with the launch of Roivant. Fast-forward to 2022, and the FDA has granted six approvals for medicines developed at Vants launched by Roivant, most notably VTAMA for plaque psoriasis. This revolutionary company has made waves in the pharmaceutical industry, and it’s only the beginning.
In January 2021, Vivek took a step back from his role as CEO of Roivant, but continued to serve as Chairman until February 20, 2023. During his tenure, he provided invaluable guidance and leadership that allowed the company to thrive and continue to grow.
We are deeply thankful for Vivek’s leadership and vision that has shaped Roivant since its founding in 2014. His mission to transform the development and commercialization of meaningful therapies has become ingrained in the company’s DNA, and we are grateful for his contributions to the board and the organization. We wish Vivek all the best in his future endeavors.
About Roivant Sciences
At Roivant, our mission is to revolutionize healthcare and improve patient outcomes by tackling inefficiencies head-on. We strive to create transformative medicines quickly and efficiently through the use of cutting-edge technology and innovative talent. We have even gone a step further to launch our own “Vants”; agile and ambitious biopharmaceutical and health technology companies that are powered by the Roivant platform. Our goal is to empower patients and make healthcare more accessible.